{"id":"W3039580871","doi":"10.1016/j.ygyno.2020.06.493","title":"Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study","year":2020,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":78,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Cancer Institute; AstraZeneca; Genentech; Bristol-Myers Squibb Canada; AbbVie; Eli Lilly and Company","keywords":"Medicine; Gynecologic oncology; Internal medicine; Cervical cancer; Progression-free survival; Oncology; Bevacizumab; Population; Adverse effect; Phases of clinical research; Stage (stratigraphy); Chemotherapy; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00300332,0.001179866,0.003762454,0.0005114764,0.001387122,0.00002886952,0.00209197,0.002711891,0.005669525],"category_scores_gemma":[0.002317128,0.001031265,0.0005809658,0.0007766709,0.001150324,0.0003886008,0.001089383,0.001933379,0.0002778883],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001460187,"about_ca_system_score_gemma":0.001424933,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004405513,"about_ca_topic_score_gemma":0.001349897,"domain_scores_codex":[0.9856206,0.007259666,0.002855324,0.002102784,0.0002154485,0.001946132],"domain_scores_gemma":[0.9886972,0.007325444,0.001857762,0.001329482,0.0005089518,0.0002811247],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.0497722,0.2095959,0.01234306,0.0001219098,0.002982841,0.0007413721,0.04077453,0.00006337816,0.471184,0.0003285662,0.004334522,0.2077577],"study_design_scores_gemma":[0.0705254,0.5754072,0.03673139,0.000006625779,0.0009167283,0.0001443859,0.04260924,0.00004857175,0.006796166,0.0001484704,0.2656398,0.001025987],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9826824,0.002512369,0.0001176471,0.001530529,0.003360863,0.007546606,0.0002854592,0.0004180953,0.001545998],"genre_scores_gemma":[0.9926502,0.0001470155,0.0005940978,0.003087028,0.0003078266,0.002128851,0.0005125203,0.000124393,0.0004480811],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4643879,"threshold_uncertainty_score":0.9999129,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06016707646096833,"score_gpt":0.3463446853480107,"score_spread":0.2861776088870424,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}